Harrow

HROW

Market cap $1.35B

Harrow Inc. (NASDAQ: HROW) posted mixed results for the fourth quarter on Tuesday.

NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner's 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida.

Harrow (HROW) is downgraded to 'Sell' as recent earnings reveal persistent low margins and overvaluation despite a 25% share price drop. FY25 revenue grew 36% YoY to $272.3M, but missed ambitious guidance and was aided by non-recurring customer stocking; future growth is back-loaded and costly. HROW's high debt load and rising interest expenses erode cash generation, with management relying on increased S&M spend and acquisitions for growth.

Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript

Harrow, Inc. remains a compelling long-term and trading opportunity, especially attractive in the mid-$30s and lower $40s after recent pullbacks. HROW delivered strong Q4 2025 revenue growth of 33% YoY to $89.1M, with annual sales up 36% and adjusted EBITDA up 54% to $61.9M. Key product lines IHEEZO and VEVYE posted record results, while TRIESENCE relaunch is in early growth stages and ImprimisRx revenue is intentionally shifting toward higher-margin products.

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to support a planned Phase 3 clinical trial evaluating TRIESENCE (preservative-free triamcinolone acetonide injectable suspension) 40 mg/mL for the treatment of ocular inflammation and pain following cataract surgery.

Harrow (HROW) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.25 per share a year ago.

Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024 GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025 Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025 Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024 Cash and cash equivalents of $72.9 million as of December 31, 2025 Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of 2026 and $203 million to $226 million in the second half of 2026 Full-year 2026 Adjusted EBITDA guidance of $80 million to $100 million A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.

This data center parts provider hit an all-time high on Monday. And a biotech stock is building a base.

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.